These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38169017)

  • 21. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer.
    McGinn O; Gupta VK; Dauer P; Arora N; Sharma N; Nomura A; Dudeja V; Saluja A; Banerjee S
    Sci Rep; 2017 Aug; 7(1):7872. PubMed ID: 28801636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minnelide reduces tumor burden in preclinical models of osteosarcoma.
    Banerjee S; Thayanithy V; Sangwan V; Mackenzie TN; Saluja AK; Subramanian S
    Cancer Lett; 2013 Jul; 335(2):412-20. PubMed ID: 23499892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
    Cole CB; Morelli MP; Fantini M; Miettinen M; Fetsch P; Peer C; Figg WD; Yin T; Houston N; McCoy A; Lipkowitz S; Zimmer A; Lee JM; Pavelova M; Villanueva EN; Trewhitt K; Solarz BB; Fergusson M; Mavroukakis SA; Zaki A; Tsang KY; Arlen PM; Annunziata CM
    J Exp Clin Cancer Res; 2023 Mar; 42(1):76. PubMed ID: 36991390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.
    Kim ST; Kim SY; Lee J; Kim K; Park SH; Park YS; Lim HY; Kang WK; Park JO
    BMC Cancer; 2018 Nov; 18(1):1103. PubMed ID: 30419860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.
    Banerjee S; Sangwan V; McGinn O; Chugh R; Dudeja V; Vickers SM; Saluja AK
    J Biol Chem; 2013 Nov; 288(47):33927-33938. PubMed ID: 24129563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia.
    Kang D; Pan X; Song Y; Liu Y; Wang D; Zhu X; Wang J; Hu L
    Eur J Med Chem; 2022 Dec; 243():114694. PubMed ID: 36115206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death.
    Chen Z; Sangwan V; Banerjee S; Mackenzie T; Dudeja V; Li X; Wang H; Vickers SM; Saluja AK
    Mol Cancer; 2013 Sep; 12(1):105. PubMed ID: 24025188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma.
    Jacobson BA; Chen EZ; Tang S; Belgum HS; McCauley JA; Evenson KA; Etchison RG; Jay-Dixon J; Patel MR; Raza A; Saluja AK; D'Cunha J; Kratzke RA
    Genes Cancer; 2015 Mar; 6(3-4):144-52. PubMed ID: 26000097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
    Kelly CM; Shoushtari AN; Qin LX; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Mcfadyen C; Sjoberg A; Singer S; DeMatteo RP; Hwang S; Heinemann MH; Francis JH; Antonescu CR; Chi P; Tap WD
    Invest New Drugs; 2019 Apr; 37(2):282-290. PubMed ID: 30101387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.
    Bang YJ; Takano T; Lin CC; Fasanmade A; Yang H; Danaee H; Asato T; Kalebic T; Wang H; Doi T
    Cancer Res Treat; 2018 Apr; 50(2):398-404. PubMed ID: 28494535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation.
    MacKenzie TN; Mujumdar N; Banerjee S; Sangwan V; Sarver A; Vickers S; Subramanian S; Saluja AK
    Mol Cancer Ther; 2013 Jul; 12(7):1266-75. PubMed ID: 23635652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
    Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
    Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide.
    Banerjee S; Nomura A; Sangwan V; Chugh R; Dudeja V; Vickers SM; Saluja A
    Clin Cancer Res; 2014 May; 20(9):2388-99. PubMed ID: 24634377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minnelide/Triptolide Impairs Mitochondrial Function by Regulating SIRT3 in P53-Dependent Manner in Non-Small Cell Lung Cancer.
    Kumar A; Corey C; Scott I; Shiva S; D'Cunha J
    PLoS One; 2016; 11(8):e0160783. PubMed ID: 27501149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broad targeting of triptolide to resistance and sensitization for cancer therapy.
    Hou ZY; Tong XP; Peng YB; Zhang BK; Yan M
    Biomed Pharmacother; 2018 Aug; 104():771-780. PubMed ID: 29807227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minnelide, a prodrug, inhibits cervical cancer growth by blocking HPV-induced changes in p53 and pRb.
    Ramakrishnan V; de Haydu C; Wilkinson P; Hooda U; Giri B; Oleas JM; Rive V; Roy S; Dudeja V; Slomovitch B; Saluja A; Ramakrishnan S
    Am J Cancer Res; 2021; 11(5):2202-2214. PubMed ID: 34094678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.